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Abstract
Background: There is uncertainty as to which intake of vitamin D is needed to suppress PTH and maintain normal
bone metabolism throughout winter at northern latitudes. We aimed to investigate whether four weeks’ daily
supplementation with 10 μg vitamin D3 from fish oil produced a greater change in serum vitamin D metabolites,
parathyroid hormone, and bone turnover in healthy adults compared with solid multivitamin tablets. Furthermore,
it was studied whether age, gender, ethnic background, body mass index, or serum concentrations at baseline
predicted the magnitude of change in these parameters.
Methods: Healthy adults aged 19–48 years living in Oslo, Norway (59°N) were randomised to receive a daily dose
of 10 μg vitamin D3 given as fish oil capsules or multivitamin tablets during four weeks in late winter. Serum
samples from baseline and after 28 days were analysed for 25-hydroxyvitamin D (s-25(OH)D), 1,25-dihydroxyvitamin
D (s-1,25(OH)2D), intact parathyroid hormone (s-iPTH), and osteoclast-specific tartrate-resistant acid phosphatase 5b
(s-TRACP). Fifty-five eligible participants completed the intervention (74% of those randomised).
Results: S-25(OH)D increased by mean 34.1 (SD 13.1) nmol/l, p< 0.001; s-iPTH decreased by mean 1.2 (SD 2.5)
pmol/l, p = 0.001; s-1,25(OH)2D increased by mean 13 (SD 48) pmol/l, p = 0.057; and s-TRACP increased by mean
0.38 (SD 0.33) U/l, p< 0.001. For all these parameters, there was no difference between fish oil and multivitamin
formulation. Baseline concentrations were the only independent predictors of changes in biochemical parameters.
Conclusions: Four weeks of daily supplementation with 10 μg vitamin D3 decreased mean s-iPTH and increased
s-TRACP concentration, and this did not differ by mode of administration. Our results suggest an increased bone
resorption following vitamin D supplementation in young individuals, despite a decrease in parathyroid hormone
levels.
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Background
Low vitamin D status is commonly observed at northern
latitudes such as in Scandinavia during wintertime, with
a drop in serum concentrations of 25-hydroxyvitamin D
(s-25(OH)D) and a corresponding increase in serum
parathyroid hormone levels (PTH) and bone turnover
[1,2]. In addition to latitude and season, individual sun
exposure and vitamin D supplementation are strong pre-
dictors of vitamin D status [1]. Maintaining s-25(OH)D
and suppressing PTH through winter is expected to be
beneficial in order to prevent bone resorption. Possible
direct means of increasing wintertime vitamin D status at
northern latitudes may be increased fortification of foods
[3], or increased supplementation. Current recom-
mended dietary intake of vitamin D for adults in
European countries and the US varies between 0–15 μg/
day (20 μg/day for elderly in the US) [4,5]. Daily supple-
mentation with 10 μg (400 IU) vitamin D is recom-
mended to elderly individuals with low sun exposure in
the Nordic countries [6]. However, there is uncertainty as
to which supplemental dose is needed in order to main-
tain 25(OH)D levels associated with PTH suppression
and normal bone metabolism. In an experimental study
performed in Omaha (41°N) it was estimated that daily
oral supplementation with 12.5 μg (500 IU) may be
required in order to maintain autumn s-25(OH)D levels
of 70 nmol/l through winter [7]. Daily oral supplementa-
tion with 10 μg (400 IU) or 20 μg (800 IU) vitamin D3
prevented increase in PTH and bone turnover during
winter in healthy men in Helsinki, Finland (60°N)
(n = 48) [8]. There seems to be large variation in s-25
(OH)D in response to oral supplementation. According
to a summary of various studies published up to 1999
[9], a daily dose of 10 μg (400 IU) vitamin D led to an
average increase in s-25(OH)D of 31 nmol/l, although
with large variation between studies, suggesting that add-
itional factors may influence the degree of increase. A
systematic review concluded that the degree of PTH sup-
pression achieved by vitamin D supplementation depends
not only on baseline PTH and increase in s-25(OH)D,
but also on the subjects’ age and mobility [10]. Healthy
young students in Coleraine, Northern Ireland (55°N)
who received a daily oral supplement of 15 μg (600 IU)
vitamin D3 for 8 weeks in late winter, increased their
mean s-25(OH)D from 47.9 to 86.5 nmol/l, but the sup-
plementation did not influence PTH levels or bone turn-
over significantly [11]. In a recent 2-center double-blind
placebo-controlled study from the same group, 215 per-
sons aged 20–40 received 0, 5, 10, or 15 μg vitamin D3
daily during 22 weeks in late winter, but supplementation
did not affect PTH levels or bone turnover [12]. Elderly
osteoporotic women in sunshine abundant São Paulo,
Brazil (23°S) who received 10 μg (400 IU) vitamin D3
daily for three months increased their mean s-25(OH)D
from 46.7 to 59.5 nmol/l, whereas PTH levels or bone
turnover were not significantly affected [13].
In our experimental study performed in Oslo (59°N)
during late winter, we found a similar effect of fish oil
capsules and multivitamin D tablets on increase in s-25
(OH)D [14]. We here present results for the predefined
secondary objectives of the study: (a) to compare
changes in s-1,25(OH)2D, s-iPTH and s-TRACP in the
fish oil capsule vs. multivitamin tablet groups, and (b) in
the supplement groups combined, to investigate whether
the magnitude of change in s-25(OH)D and the above
mentioned metabolites was predicted by ethnic back-
ground, body mass index, age, gender, or serum concen-
trations at baseline.
Methods
Study subjects
Subjects with Norwegian (in the following quoted as
Norwegians) and other ethnic background were
recruited primarily among medical students and nurse
students in Oslo. In addition, subjects with Sri Lankan
Tamil background (in the following quoted as Tamils)
were recruited through an organisation for Tamils in
Oslo (Tamil Resource and Counselling Centre). The par-
ticipants recruited through medical or nursing school
attended pre-test baseline examination within the period
14–17 February, and the participants recruited through
the Tamil Resource and Counselling Centre attended
within the period 11–14 March. The four-week inter-
vention was thus completed in mid-April by the latest, i.
e. prior to Easter holidays when sunlight exposure would
be expected to increase. Those who already took a vita-
min D supplement regularly, defined as once a week or
more, or had been travelling to sunny areas or used a
tanning bed during the previous three months, were
defined as ineligible to participate. A total of 74 subjects
of the 143 subjects who had agreed to participate
(51.7%), were randomised to receive multivitamin tablets
or fish oil capsules [14].
Intervention
The participants each received a daily supplement of
10 μg (400 IU) vitamin D3 from one multivitamin tablet
of type Vitaplex ABCD (Cederroth AS, Revetal, Norway),
or one fish oil capsule, specially manufactured for this
study by Peter Möller (now Möller’s, Oslo, Norway). Vita-
min D3 content of the supplements was determined by an
independent laboratory (AS Vitas, Oslo, Norway). Mean
content was 9.79 μg per multivitamin tablet (SD 1.51), and
9.99 μg per fish oil capsule (SD 0.23), respectively. In
addition to vitamin D3, the multivitamin tablets were
declared by the manufacturer to contain 750 μg vitamin
A, 1.5 mg vitamin B1, 1.7 mg vitamin B2, 1.5 mg vitamin
B6, 20 mg niacin, 5 mg pantothenic acid, and 30 mg
Holvik et al. BMC Endocrine Disorders 2012, 12:7 Page 2 of 8
http://www.biomedcentral.com/1472-6823/12/7
vitamin C. The fish oil capsules contained 660 μg vitamin
A, 3.7 mg vitamin E, and 0.5 g n-3 polyunsaturated fatty
acids, as analysed by the manufacturer. Retinol concentra-
tion in the fish oil capsules was standardised to be similar
to the multivitamin tablets. Supplements were handed out
to each participant at baseline, along with a self-
administered compliance form. Participants were encour-
aged to maintain their usual diet during the study period.
The tablets or capsules were ingested daily for 4 weeks,
which is considered to be a sufficient duration in order
to reach equilibrium (plateau concentration) in s-25
(OH)D [9].
Data collection
A venous serum sample was drawn on day 1, prior to
the intervention, and on day 29, the day subsequent to
ingesting the final tablet or capsule. The participants
completed a self-administered three-page questionnaire
at baseline. During completion of the questionnaire, they
had the possibility to ask for assistance (i.e. clarification
of questions, or language issues) from one of the project
leaders. The questionnaire included questions about
usual intake of vitamin D-containing foods, supplement
use, clothing and sun exposure habits, self-reported
height and weight, date of birth, education, and ethnic
background. At follow-up, all participants’ height and
weight were measured with an electronic height- and
weight-measuring device.
Serum sample handling and analyses
Blood samples were centrifuged (10 min, 2000 g at 10 °C)
within 30 minutes after blood collection and sera were
immediately frozen and kept at −70 °C until analyzed.
Pre- and post-intervention serum from all participants
were analysed blinded, in one batch at the Hormone La-
boratory (Department of Endocrinology, Oslo University
Hospital Aker, Oslo, Norway).
S-25(OH)D was measured by radioimmunoassay (RIA)
(DiaSorin, Stillwater, MN, USA). This assay measures
both 25(OH)D3 and 25(OH)D2. The intra- and interassay
coefficients of variation (CV) were 6% and 14-15%, re-
spectively. The detection limit was 6 nmol/l.
Intact PTH (iPTH) were measured by chemilumi-
noimmunometric assay (DPC, Los Angeles, CA, USA).
The intra- and interassay CVs for iPTH were 4% and
10%, respectively.
S-1,25(OH)2D was measured by competitive RIA (Dia-
Sorin, Stillwater, MN, USA). Prior to the 1,25(OH)2D de-
termination, serum lipids and interfering vitamin D
metabolites were removed by chromatography on a
C18OH column. Cross reaction with 25(OH)D after
chromatography is noted to be 0.002%. The intra- and
interassay CVs for the s-1,25(OH)2D assay were 7 and
14%, respectively. The limit of detection was 12 pmol/l.
S-TRACP was measured by enzyme activity assessment
after immune extraction (Suomen Bioanalytiikka Oy,
Oulu, Finland). This assay measures the active isoform 5b
derived from osteoclasts. The intra- and interassay CVs
for s-TRACP were 5–12 and 8–14% respectively.
Statistical analysis
The data were analysed in SPSS and Stata. According to
normality plots, the dependent variables: Δ25(OH)D, Δ
PTH, Δ1,25(OH)2D and ΔTRACP did not deviate sub-
stantially from a normal distribution, and non-
parametric tests yielded similar results. Therefore, means
and distributions are presented for continuous variables,
and percentages are presented for categorical variables.
Pre- and post-intervention concentration of biochemical
parameters were compared by paired samples t tests.
Crude differences between the two intervention groups
were tested using t test. Potential predictors of change in
biochemical parameters were analysed using linear
regression.
Results
Participants
Of the 74 subjects included in the study, 10 violated the
eligibility criteria according to the questionnaire at base-
line, three reported an intake of less than 26 tablets or
capsules during the 28-day intervention period, three
were lost to follow-up, two had their second blood sam-
ple taken three days before schedule, and one withdrew.
The number of participants excluded was similar in the
two intervention groups (nine and ten, respectively).
Thus, 55 eligible participants completed the study. Of
these, 36 had ethnic Norwegian background, 12 had
Tamil background, and seven had various other ethnic
backgrounds. Characteristics of the study participants
are presented in Table 1.
Effect of supplementation on vitamin D status
Mean (SD) s-25(OH)D in the sample increased from
44.3 (23.6) nmol/l to 78.4 (24.5) nmol/l, with a mean
(SD) increase (Δ25(OH)D) of 34.1 (13.1) nmol/l
(Table 2). Individual Δ25(OH)D ranged from −12 nmol/l
to 58 nmol/l. Δ25(OH)D did not differ by type of sup-
plement, as previously published [14]. At baseline, one
person had s-25(OH)D <12.5 nmol/l and 13 persons
(24%) had s-25(OH)D< 25 nmol/l. Four persons (7%)
had s-25(OH)D> 75 nmol/l. At follow-up, none had s-
25(OH)D <25 nmol/l. Five participants (9%) had s-25
(OH)D <50 nmol/l. Twenty-nine participants (53%) had
s-25(OH)D >75 nmol/l at follow-up.
Effect of supplementation on PTH and TRACP
S-iPTH decreased by mean 1.2 pmol/l, from 5.9
pmol/l to 4.7 pmol/l (Table 2), and the decrease did
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not differ significantly by type of supplement. The
decrease was significant in the multivitamin group
where s-iPTH at baseline was accidentally higher.
There was an overall borderline statistically signifi-
cant increase in s-1,25(OH)2D. Individual Δs-1,25
(OH)2D showed a large variation, from −135 to 120
pmol/l. S-TRACP increased significantly from mean
2.65 to mean 3.03 U/L during supplementation.
Potential predictors of effect of supplementation
Results of linear regression analysis are shown in Table 3.
Baseline s-25(OH)D was predicted only by ethnic back-
ground, Norwegians having unadjusted mean 33 (95%
CI 20, 46) nmol/l higher baseline s-25(OH)D than
Tamils. However, ethnic background did not affect in-
crease in vitamin D status. Mean (SD) increase in s-25
(OH)D was 33.8 (14.1) in Norwegians and 36.2 (10.0) in
Table 1 Background characteristics of participants (n = 55)
Age, years, mean (range) 28 (19–48)
Gender, n (%) women 35 (63.6)
Body mass index, kg/m2, mean (SD) 23.7 (3.8)
Daily use of vitamin D-containing butter or margarine on bread or in cooking, n (%) 25 (45.5)
Regular consumption of vitamin D enriched milk, n (%) 14 (25.5)
Intake of fatty fish at least twice a week, n (%) 32 (58.2)
Habitual use of dietary supplements other than vitamin D, n (%) 7 (12.7)
Common use of sunscreen on sunny days, n (%) 18 (32.7)
Exposes skin to direct sunlight> 10 minutes on sunny days, n (%) 49 (89.1)
Spends on average more than 2 hours outdoors during a sunny week, n (%) 36 (65.5)
Table 2 Mean (SD) unadjusted serum levels of markers of the vitamin D endocrine system and bone turnover at
baseline and follow-up according to type of supplement
Variable n Mean (SD)
serum level at
baseline
Mean (SD) serum
level at follow-up
Mean (SD)
change
during
intervention
p value (2)
s-25(OH)D (nmol/l)
Overall 55 44.3 (23.6) 78.4 (24.5) 34.1 (13.1) <0.001
Fish oil capsules 27 48.5 (24.8) 80.4 (25.0) 31.9 (15.3) <0.001
Multivitamin tablets 28 40.3 (22.0) 76.5 (24.3) 36.2 (10.4) <0.001
p value (1) 0.20 0.56 0.22
s-iPTH (pmol/l)
Overall 55 5.9 (2.6) 4.7 (2.1) −1.2 (2.5) 0.001
Fish oil capsules 27 5.7 (2.6) 4.9 (2.5) −0.9 (2.8) 0.13
Multivitamin tablets 28 6.0 (2.7) 4.5 (1.6) −1.4 (2.2) 0.002
p value (1) 0.77 0.52 0.40
s-1,25(OH)2D (pmol/l)
Overall 53 121 (41) 134 (38) 13 (48) 0.057
Fish oil capsules 27 128 (38) 136 (34) 8 (45) 0.37
Multivitamin tablets 26 113 (43) 131 (42) 18 (50) 0.09
p value (1) 0.20 0.64 0.46
s-TRACP (U/l)
Overall 54 2.65 (0.70) 3.03 (0.69) 0.38 (0.33) <0.001
Fish oil capsules 27 2.59 (0.80) 3.01 (0.77) 0.43 (0.31) <0.001
Multivitamin tablets 27 2.71 (0.61) 3.04 (0.60) 0.34 (0.36) <0.001
p value (1) 0.53 0.87 0.32
(1) Differences between types of supplement are tested using t test.
(2) Paired-samples t test for comparison of individual pre- and post-intervention concentration.
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Table 3 Predictors of change in biochemical parameters during four weeks of vitamin D3 supplementation (n= 55)
Dependent variable Δs-25(OH)D (nmol/l) Δs-iPTH (pmol/l) Δs-1,25(OH)2D (pmol/l) Δs-TRACP (U/L)
B
(95% CI)
p value B
(95% CI)
p value B
(95% CI)
p value B
(95% CI)
p value
Type of supplement (solid multivitamin tablet
vs. gelatine fish oil capsule with n-3 fatty acids) (1)
3.5 (2) (−3.6, 10.6) 0.33 −0.4 (−1.5, 0.6) 0.39 −1 (−22, 19) 0.89 −0.08 (−0.25, 0.10) 0.40
Age, per 10 years 1.4 (−3.2, 6.0) 0.54 −0.5 (−1.3, 0.4) 0.31 −10 (−27, 7) 0.24 0.07 (−0.05, 0.19) 0.25
Gender, men vs. women 1.0 (−6.4, 8.5) 0.78 −1.3 (−2.5, 0.3) 0.11 18 (−8, 46) 0.17 0.04 (−0.16, 0.23) 0.71
Body mass index, per 5 kg/m2 −1.0 (−5.7, 3.7) 0.68 −0.3 (−1.2, 0.6) 0.48 −9 (−26, 8) 0.30 0.05 (−0.07, 0.17) 0.41
Ethnic background, Tamil vs. Norwegian 2.7 (−6.0, 11.3) 0.54 −0.5 (−2.2, 1.2) 0.54 −18 (−51, −14) 0.26 0.27 (0.05, 0.49) 0.016
Baseline s-25(OH)D, per 10 nmol/l −1.1 (−2.6, 0.4) 0.13 0.2 (−0.1, 0.5) 0.10 −3 (−8, 3) 0.31 −0.03 (−0.07, 0.01) 0.10
Baseline s-iPTH, per 5 pmol/l 4.4 (−2.3, 11.2) 0.20 −3.2 (−4.2, −2.3) < 0.001 −13 (−38, 12) 0.30 −0.04 (−0.22, 0.14) 0.66
Baseline s-1,25(OH)2D, per 10 pmol/l −0.3 (−1.2, 0.6) 0.51 0.0 (−0.2, 0.1) 0.71 −8 (−10, −5) < 0.001 < −0.01 (−0.03, 0.02) 0.81
Baseline s-TRACP, per U/l −4.7 (−9.8, 0.3) 0.07 0.1 (−0.9, 1.1) 0.86 9 (−10, 28) 0.34 −0.13 (−0.26, -0.01) 0.039
1 Groups are randomised with regard to type of supplement. The analysis of type of supplement is adjusted for baseline serum concentration of the respective dependent variables, while the other analyses in the
table are unadjusted.
2 Result previously published in: Holvik K et al., Br J Nutr 2007; 98: 620–5.
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Tamils, p = 0.60. No background characteristics were sig-
nificantly associated with increase in s-25(OH)D during
supplementation (Table 3). The changes in the biochem-
ical parameters (except 25(OH)D) were inversely asso-
ciated with their baseline concentrations. Decrease in s-
iPTH during supplementation tended to be larger when
baseline s-25(OH)D was lower (Figure 1).
There was a significant association between ethnic
background and ΔTRACP, Tamils having higher increase
in s-TRACP than Norwegians (Table 3). This was not
significant when adjusting for the lower baseline s-
TRACP in Tamils (p = 0.07).
There was no effect of type of supplement (fish oil
capsule or multivitamin tablet) on change in any bio-
chemical parameter.
Discussion
We found that supplementation with 10 μg vitamin D3/
day administered for four weeks in late winter led to
vitamin D sufficiency (s-25(OH)D> 50 nmol/l) in
healthy adults of ethnic Norwegian background, but not
completely so in Tamils living in Oslo (59°N). This was
due to a very low baseline vitamin D status in Tamils,
which we have also observed previously [15]. In spite of
the strict exclusion criteria, vitamin D status at baseline
was not very low in ethnic Norwegian participants. A
large proportion of the study sample were medical and
nursing students, probably more health-conscious than
the general population, and may have had a relatively
high intake of vitamin D intake during winter. However,
the supplementation was equally efficient regardless of
ethnic background, and led to an overall mean increase in
s-25(OH)D of 34.1 nmol/l in the course of four weeks.
We found no effect of type of vitamin D supplement (solid
multivitamin tablet or fish oil capsule containing n-3 fatty
acids) on either increase in vitamin D status [14] or in the
change in parathyroid hormone, the active vitamin D hor-
mone, or osteoclast activity. As far as we are aware, this is
the first randomised trial to compare the effect of two dif-
ferent modes of administration of vitamin D3 on markers
of the vitamin D endocrine system and bone turnover.
S-25(OH)D above 50 nmol/l has been associated with
optimal musculoskeletal function in elderly [16], and this
level is commonly used as cut-off for vitamin D suffi-
ciency in European populations [17-19]. However, some
advocate a target s-25(OH)D in the adult European and
US population of at least 75 nmol/l for optimal fall and
fracture prevention, and this requires daily supplementa-
tion of at least 18–25 μg (700–1000 IU) [20]. However,
few intervention studies have focused on supplementa-
tion in young adult individuals and its influence on mar-
kers of bone health.
Unlike other intervention studies with a similar dose
of vitamin D [8,11-13], we observed a significant sup-
pression of PTH as well as increased bone turnover in
our study.
Vitamin D supplementation is expected to prevent
bone loss mainly by slowing bone resorption. Due to the
short follow-up time, we expected any effect on bone
turnover likely to be observed in resorption rather than
formation. The TRACP isoform 5b is released by osteo-
clasts early in their differentiation, and this enzyme is
specifically a marker of number of osteoclasts rather
than of their resorptive activity. In healthy individuals,
however, the osteoclast number and their resorptive ac-
tivity is expected to be highly correlated [21]. TRACP 5b
was also studied in the recent Finnish supplementation
study in healthy men aged 21–49 years (n=48) [8]. The
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Figure 1 Relationship between vitamin D status at baseline and change in PTH (n = 55).
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investigators observed a decrease in this marker throughout
winter (6 months) regardless of whether the participants
received placebo, 10, or 20 μg vitamin D. The bone forma-
tion marker (bone alkaline phosphatase) decreased in the
groups receiving vitamin D supplementation but was un-
altered in the placebo group.
The suggested increase in osteoclast activity in our
data in spite of the improvement in vitamin D status
and corresponding PTH suppression is surprising, but
may represent a transient high turnover state with
increased bone turnover as a result of increased bone
formation. The participants were relatively young, and
40% were below 25 years of age. Peak bone mass may
not have been acquired in all participants [22]. An
increased bone turnover may thus suggest an improved
rate of bone growth in young adults. As bone formation
and resorption are coupled processes, increased forma-
tion will follow the increase in resorption. A decrease in
PTH would be expected to suppress bone resorption,
but bone resorption is also stimulated by 1,25(OH)2D.
Local production of 1,25(OH)2D in the tissues may have
increased, while we have only measured circulating 1,25
(OH)2D. There is evidence that 25(OH)D affects osteo-
clastogenesis and bone turnover (and thereby TRACP
production) by local activation in bone cells [23]. In a
recent review, it was considered that due to this local ac-
tivation, circulating levels of 25(OH)D, and not 1,25
(OH)2D, may represent the better correlate to para-
meters of bone health [24].
There is ongoing research concerning the role of n-3
fatty acids in bone health, as bone loss due to increased
osteoclast activity may be mediated by inflammatory
cytokines, and some studies suggest a protective effect
of n-3 fatty acids on bone resorption [25,26]. In bone
marrow from ovarioectomized mice, addition of eicosa-
pentaenoic acid and docosahexaenoic acid led to signifi-
cantly reduced TRACP activity and osteoclastogenesis
[27]. A protective effect of n-3 fatty acids (0.5 g/day) in
fish oil on bone resorption was not supported in our
data in young adults, as subjects’ s-TRACP increased re-
gardless of being randomised to ingest fish oil capsules
containing omega-3 fatty acids, or solid tablets. The in-
crease in s-TRACP was even slightly higher in the group
ingesting fish oil capsules (not shown/not significant).
It cannot be excluded that an independent effect of
the supplementation on bone turnover regardless of the
observed decrease in PTH could be brought about by
factors other than vitamin D. Both intervention supple-
ments contained vitamin A (retinol). Although the evi-
dence of an effect of vitamin A on bone health is
inconsistent, some in vitro studies have shown that ret-
inoic acid directly stimulate osteoclastic bone resorp-
tion, and high intakes and serum levels of retinol
have been associated with reduced bone mineral
density or increased fracture risk in some population-
based studies [28].
Our study was a parallel-group intervention and we
did not include a placebo group. Due to the late winter-
time intervention period we did not expect any notable
background increase in vitamin D status. Moreover, any
background change in vitamin D status would be the
consequence of any unexpected behaviour in relation to
diet or sun exposure in both parallel-groups regardless
of supplement. Our study sample was restricted to not
take a regular supplement other than the intervention
supplement, use a tanning bed, or travel to sunny areas.
Any extraordinary dietary intake (e.g. large fatty fish din-
ner) would be noted on the participants’ individual com-
pliance form, and no such behaviour was reported. Also,
only those who were compliant defined as consuming at
least 26 of the 28 tablets were included in the analyses.
Thus, there is reason to expect that any observed change
in the vitamin D endocrine system is an effect of the
supplementation.
A limitation of the ethnic comparison was the differ-
ent age distributions between participants with ethnic
Norwegian and Sri Lankan Tamil background. Mean age
in the two groups differed by 14 years. While more than
half of the subjects with ethnic Norwegian background
were below 30 years of age, none of those with Sri
Lankan Tamil background were below that age. Age is
an important predictor of serum PTH [10], but limited
overlap in age between the ethnic groups in our study
makes it difficult to rule out the influence of age and
ethnic background, respectively.
Conclusions
We conclude that four weeks of daily supplementation
with 10 μg (400 IU) vitamin D3 to healthy adults during
wintertime led to a decrease in s-iPTH and an increase
in circulating TRACP. These effects did not differ by
mode of administration. In spite of different serum levels
at baseline in Norwegians and Tamils, the effect was
similar in the two ethnic groups.
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